Intended for U.S. healthcare professionals only.
For corporate information, please visit

Generic Products
In This Section

Temazepam Capsules USP CIV 7.5 mg

This information is intended for U.S. healthcare professionals only.


Temazepam Capsules USP (CIV) are indicated for the short-term treatment of insomnia (generally 7 to 10 days).


Temazepam is contraindicated in pregnant women or women who may become pregnant due to an increased risk of congenital malformations as well as risk of neonatal CNS depression.


  • Sleep disturbance may be the presenting manifestation of an underlying physical and/or psychiatric disorder. Consequently, a decision to initiate symptomatic treatment of insomnia should only be made after the patient has been carefully evaluated. The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated.
  • Behavioral changes may occur with use including aggressiveness and extroversion, bizarre behavior, agitation, hallucinations, and depersonalization.
  • Risk of the development of oversedation, dizziness, confusion, and/or ataxia increases substantially with larger doses of benzodiazepines in elderly and debilitated patients, 7.5 mg of temazepam capsules are recommended as the initial dosage for such patients.
  • Complex behaviors, such as sleep-driving, sleep-walking, etc. may occur with temazepam capsules alone at therapeutic doses, the use of alcohol and other CNS depressants with temazepam capsules appear to increase the risk of such behaviors, as does the use of temazepam capsules at doses exceeding the maximum recommended dose.
  • Withdrawal symptoms have occurred after the abrupt discontinuation of benzodiazepines.
  • Rare cases of angioedema involving the tongue, glottis or larynx have been reported in patients after taking the first or subsequent doses of sedative-hypnotics, including temazepam capsules.
  • Temazepam capsules should be administered with caution in severely depressed patients or those in whom there is any evidence of latent depression.
  • Additive effects can occur when temazepam is combined with other drugs having known hypnotic properties or CNS-depressant effects
  • Abnormal liver function tests as well as blood dyscrasias have been reported with benzodiazepines.


  • Serious adverse reactions include complex behaviors (e.g. sleep-driving, aggressiveness) and angioedema involving the tongue, glottis or larynx, hallucinations, and agitation.
  • Common adverse reactions include drowsiness and headache.


  • Pregnancy category X. Contraindicated in pregnancy.
  • Safety and effectiveness in pediatric patients have not been established.
Description Opaque Blue Cap and Opaque Pink Body
Dosage Strength 7.5 mg
Compares To Restoril™
Identification Code Imprinted “FOR SLEEP” on one side and M on the other side in red, and an opaque blue cap imprinted “7.5mg” twice in red
Rating AB


NDC # Package Size Case Quantity
0406-9960-01 100's 12

For additional information on Temazepam Capsules USP CIV 7.5 mg, call Customer Service at 1.800.325.8888 or Medical Information at 1.800.778.7898.